
INSP Stock Forecast & Price Target
INSP Analyst Ratings
Bulls say
Inspire Medical Systems Inc. has demonstrated a significant increase in its spending on direct-to-consumer advertising, which rose by 56% in the third quarter of 2025 and is expected to continue into 2026, suggesting a strategic effort to boost awareness and procedure volumes for its neurostimulation technology targeting obstructive sleep apnea. The company has reiterated its revenue guidance for 2025, with a notable increase in GAAP earnings per share, reflecting improved operational performance. Furthermore, management indicated a projected rise in average selling prices due to improved reimbursement, positioning the company for higher revenue growth and profitability going forward.
Bears say
Inspire Medical Systems has faced challenges with the launch of its new product, Inspire 5, resulting in a revised revenue and earnings per share outlook due to slower-than-anticipated adoption rates. The company has also seen a decline in advertising expenditures for 2024 and into 1H25, further indicating a tightening budget and potential revenue struggles. Additionally, a reduction in operational expenditures, particularly in research and development and selling, general, and administrative expenses, points to a cautious approach amidst headwinds affecting future growth potential, leading to a negative outlook on the stock.
This aggregate rating is based on analysts' research of Inspire Medical Systems Inc and is not a guaranteed prediction by Public.com or investment advice.
INSP Analyst Forecast & Price Prediction
Start investing in INSP
Order type
Buy in
Order amount
Est. shares
0 shares